Key GLP-1 Access Metrics and Benchmarks These figures illustrate the steep gap between ideal access (near-100% coverage, same-day approvals) and reality (sub-50% fill, multi-day delays)
By reducing caloric intake through appetite suppression, improving insulin sensitivity, and directly stimulating hepatic lipid clearance, retatrutide may address multiple drivers of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology increasingly used in UK and European clinical practice, though many NHS and NICE materials continue to use the older designation of non-alcoholic fatty liver disease (NAFLD)
A landmark, randomized, double-blind renal health study: reduces the risk of major kidney disease events by 24%, 50% greater decline in eGFR or death from renal/CV causes reduces cardiovascular (CV) events by 18%, and 20% reduction in all-cause mortality in patients with type 2 diabetes and chronic kidney disease
Tirzepatide takes it a step further by also mimicking another hormone called GIP, which works together with GLP-1 to reduce appetite and improve how your body handles food
